Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
<Bundle xmlns="http://hl7.org/fhir">
<id value="bundlepackageleaflet-en-167401fb8187f3756835cc75cca90e3c"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"/>
</meta>
<language value="en"/>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="None"/>
</identifier>
<type value="document"/>
<timestamp value="2023-06-27T10:09:22Z"/>
<entry>
<fullUrl
value="Composition/composition-en-167401fb8187f3756835cc75cca90e3c"/>
<resource>
<Composition>
<id value="composition-en-167401fb8187f3756835cc75cca90e3c"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"/>
</meta>
<language value="en"/>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><a name="Composition_composition-en-167401fb8187f3756835cc75cca90e3c"> </a><p class="res-header-id"><b>Generated Narrative: Composition composition-en-167401fb8187f3756835cc75cca90e3c</b></p><a name="composition-en-167401fb8187f3756835cc75cca90e3c"> </a><a name="hccomposition-en-167401fb8187f3756835cc75cca90e3c"> </a><a name="composition-en-167401fb8187f3756835cc75cca90e3c-en-US"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">Language: en</p><p style="margin-bottom: 0px">Profile: <a href="https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Composition-uv-epi.html">Composition (ePI)</a></p></div><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/21/1603/001</p><p><b>status</b>: Final</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi/ 100000155538}">Package Leaflet</span></p><p><b>category</b>: <span title="Codes:{http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs R}">Raw</span></p><p><b>date</b>: 2022-02-16 13:28:17+0000</p><p><b>author</b>: <a href="Organization-mah-ema.html">Organization ACME industry</a></p><p><b>title</b>: TEST PURPOSES ONLY - lumykras</p><h3>Attesters</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Mode</b></td><td><b>Time</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://hl7.org/fhir/composition-attestation-mode official}">Official</span></td><td>2022-02-16 13:28:17+0000</td></tr></table></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/21/1603/001"/>
</identifier>
<status value="final"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package Leaflet"/>
</type>
<category>
<coding>
<system
value="http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs"/>
<code value="R"/>
<display value="Raw"/>
</coding>
</category>
<subject>
<reference
value="MedicinalProductDefinition/mp167401fb8187f3756835cc75cca90e3c"/>
</subject>
<date value="2022-02-16T13:28:17Z"/>
<author>🔗
<reference value="Organization/mah-ema"/>
</author>
<title value="TEST PURPOSES ONLY - lumykras"/>
<attester>
<mode>
<coding>
<system
value="http://hl7.org/fhir/composition-attestation-mode"/>
<code value="official"/>
</coding>
</mode>
<time value="2022-02-16T13:28:17Z"/>
</attester>
<section>
<title value="B. Package Leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="B. Package Leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
<emptyReason>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/list-empty-reason"/>
<code value="unavailable"/>
</coding>
</emptyReason>
<section>
<title value="Package leaflet: Information for the user"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package leaflet: Information for the user"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"></div>
</text>
</section>
<section>
<title value="What is in this leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="What is in this leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What is in this leaflet</p><ol type="1"><li>What LUMYKRAS is and what it is used for</li><li>What you need to know before you take LUMYKRAS</li><li>How to take LUMYKRAS</li><li>Possible side effects</li><li>How to store LUMYKRAS</li><li>Contents of the pack and other information</li></ol></div>
</text>
</section>
<section>
<title value="1. What lumykras is and what it is used for"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="1. What lumykras is and what it is used for"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>LUMYKRAS contains the active substance sotorasib and belongs to a group of medicines known as antineoplastic agents (cancer medicines).</p><p>LUMYKRAS is used to treat adults with a type of lung cancer called non-small cell lung cancer (NSCLC) when it is advanced and has spread to other parts of the body.</p><p>LUMYKRAS is used when previous treatments were not effective in stopping the growth of the cancer, and when the cancer cells have a genetic change that allows them to produce an abnormal form of protein called KRAS G12C. Your doctor will test your cancer cells for this change beforehand to make sure that LUMYKRAS is right for you.</p><p>How does LUMYKRAS work?</p><p>The abnormal KRAS G12C protein, acts to help make cancer cells grow out of control. LUMYKRAS attaches to the protein and stops it from working, which may slow down or stop the growth of the cancer.</p><p>If you have any questions about how LUMYKRAS works or why this medicine has been prescribed for you, ask your doctor, pharmacist, or nurse.</p></div>
</text>
</section>
<section>
<title value="2. What you need to know before you take lumykras"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text
value="2. What you need to know before you take lumykras"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Do not take LUMYKRAS</p><ul><li>if you are allergic to sotorasib or any of the other ingredients of this medicine (listed in section 6). Warnings and precautions</li></ul><p>Talk to your doctor, pharmacist, or nurse before taking LUMYKRAS.</p><p>Tell your doctor, pharmacist or nurse if you have a history of liver problems. Your doctor may carry out blood tests to check your liver function, and may decide to either reduce the dose of LUMYKRAS or stop your treatment.</p><p>Tell your doctor if you have ever had any other lung problems. Some lung problems may get worse during treatment with LUMYKRAS, as LUMYKRAS may cause inflammation of the lungs during treatment. Symptoms may be similar to those from lung cancer. Tell your doctor right away if you have any new or worsening symptoms including difficulty in breathing, shortness of breath, or cough with or without mucous, or fever.</p><p>Children and adolescents</p><p>LUMYKRAS has not been studied in children or adolescents. Treatment with LUMYKRAS is not recommended in persons under 18 years of age.</p><p>Other medicines and LUMYKRAS</p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription, vitamins and herbal supplements. This is because LUMYKRAS can affect the way some other medicines work, and some other medicines can affect the way LUMYKRAS works.</p><p>The following medicines may reduce how well LUMYKRAS works:</p><ul><li>Medicines used to reduce stomach acid and to treat stomach ulcers, indigestion and heartburn (see section 3) such as:</li></ul><ul><li>dexlansoprazole, esomeprazole, lansoprazole, omeprazole, pantoprazole sodium, or rabeprazole (medicines known as proton pump inhibitors )</li><li>ranitidine, famotidine, cimetidine (medicines known as H2 receptor antagonists )</li></ul><ul><li>Rifampicin (used to treat tuberculosis)</li><li>Medicines used to treat epilepsy called phenytoin, phenobarbital or carbamazepine (also used to treat nerve pain)</li><li>St. John s wort (herbal medicine used to treat depression)</li><li>Enzalutamide (used to treat prostate cancer)</li></ul><p>LUMYKRAS may reduce how well the following medicines work:</p><ul><li>Medicines used to treat severe pain, such as alfentanil or fentanyl</li><li>Medicines used in organ transplantation to prevent organ rejection, such as cyclosporine, sirolimus, everolimus, or tacrolimus</li><li>Medicines used to reduce cholesterol levels, such as simvastatin, atorvastatin, or lovastatin</li><li>Midazolam (used to treat acute seizures or as a sedative before or during surgery or medical procedures)</li><li>Medicines used to treat heart rhythm problems, such as dronedarone or amiodarone</li><li>Medicines known as anticoagulants that stop your blood clotting, such as rivaroxaban or apixaban</li></ul><p>LUMYKRAS may increase the risk for side effects with the following medicines:</p><ul><li>Medicines used to treat certain cancers or inflammatory conditions, such as methotrexate, mitoxantrone, topotecan or lapatinib</li><li>Medicines used to treat heart failure, such as digoxin</li><li>Medicines used to lower cholesterol, such as rosuvastatin</li></ul><p>Contraception</p><p>If you take LUMYKRAS whilst using oral contraceptives, the oral contraceptives may be ineffective. In addition, you should use another reliable method of birth control such as a barrier method (e.g. condom) so you do not become pregnant while you are taking this medicine. Talk to your doctor about the right methods of contraception for you and your partner.</p><p>Pregnancy, breast-feeding and fertility</p><p>Pregnancy</p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.</p><p>You should not become pregnant while taking this medicine because the effects of LUMYKRAS in pregnant women are not known, it could harm the baby. If you are able to become pregnant, you must use highly effective contraception while on treatment and for at least 7 days after stopping treatment.</p><p>Breast-feeding</p><p>Do not breast-feed while taking this medicine and for 7 days after the last dose. This is because it is not known whether the ingredients in LUMYKRAS pass into breast milk and could therefore harm your baby.</p><p>Driving and using machines</p><p>LUMYKRAS has no marked influence on the ability to drive and use machines.</p><p>LUMYKRAS contains lactose</p><p>If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.</p><p>LUMYKRAS contains sodium</p><p>This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially sodium- free .</p></div>
</text>
</section>
<section>
<title value="3. How to take lumykras"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="3. How to take lumykras"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>Do not change your dose or stop taking LUMYKRAS unless your doctor or pharmacist tells you to. Your doctor or pharmacist may decrease the dose or stop your medicine depending on how well you tolerate it.</p><ul><li>The recommended dose is eight tablets (960 mg) once a day. Take your daily dose of LUMYKRAS by mouth once a day, at the same time each day.</li><li>LUMYKRAS can be taken with or without food.</li><li>Swallow the tablets whole. You can disperse the tablets in water but do not chew, crush, or split the tablets.</li><li>If you cannot swallow LUMYKRAS tablets whole:</li></ul><ul><li>Place your daily dose of LUMYKRAS in half a glass (not less than 120 mL) of plain, room temperature drinking water, without crushing the tablets. Do not use any other liquids, including acidic beverages (e.g. fruit juices).</li><li>Swirl gently until the tablets are in small pieces (the tablets will not dissolve completely). The appearance of the mixture may range from pale to bright yellow.</li><li>Drink the mixture right away.</li><li>Rinse the glass with an additional half a glass of water and drink right away to make sure that you have taken the full dose of LUMYKRAS.</li><li>If you do not drink all of the mixture immediately, stir the mixture again before you finish drinking it. Drink all of the mixture within two hours of preparation.</li></ul><ul><li>If necessary, your doctor may recommend you receive LUMYKRAS through a feeding tube.</li></ul><p>If you need to take a medicine to reduce stomach acid such as a proton pump inhibitor or an H2 receptor antagonist, take LUMYKRAS with an acidic beverage (such as cola) . Alternatively, you may use a local antacid (such as magnesium hydroxide or calcium carbonate) and, in that case, LUMYKRAS should be taken either 4 hours before or 10 hours after that medicine (see section 2).</p><p>If you take more LUMYKRAS than you should</p><p>Contact your doctor, pharmacist or nurse immediately if you take more tablets than recommended.</p><p>If you vomit after taking LUMYKRAS</p><p>If you vomit after taking a dose of LUMYKRAS, do not take an extra dose. Take your next dose at your regular scheduled time.</p><p>If you forget to take LUMYKRAS</p><p>If you forget to take a dose of LUMYKRAS at your regular scheduled time, and less than 6 hours have passed, take your dose as normal. If more than 6 hours have passed from your regular scheduled time, do not take the dose. Take your next dose at your regular scheduled time the next day.</p></div>
</text>
</section>
<section>
<title value="4. Possible side effects"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="4. Possible side effects"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>Very common and serious possible side effects of LUMYKRAS are increased blood levels of certain liver enzymes (AST/ALT), which are a sign of liver problems. Your doctor may do blood tests to check how well your liver is working and may decide to either reduce the dose of LUMYKRAS or stop your treatment (see section 2).</p><p>Other possible side effects of LUMYKRAS may include:</p><p>Very common (may affect more than 1 in 10 people)</p><ul><li>Diarrhoea</li><li>Feeling sick (nausea)</li><li>Feeling tired</li><li>Vomiting</li><li>Constipation</li><li>Stomach pain</li><li>Fever</li><li>Joint pain</li><li>Back pain</li><li>Shortness of breath</li><li>Cough</li><li>Low red blood cell count (anaemia) which may cause tiredness and fatigue</li><li>Headache</li></ul><p>Common (may affect up to 1 in 10 people)</p><ul><li>High levels of some enzymes including blood enzymes seen in tests (increased alkaline phosphatase, bilirubin and gamma-glutamyltransferase)</li><li>Liver injury</li></ul><p>Uncommon (may affect up to 1 in 100 people)</p><ul><li>Inflammation of the lungs called interstitial lung disease</li></ul><p>Reporting of side effects</p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.</p></div>
</text>
</section>
<section>
<title value="5. How to store lumykras"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="5. How to store lumykras"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the carton and blister after EXP. The expiry date refers to the last day of that month. Do not use this medicine after the expiry date which is stated on the carton and bottle after EXP. The expiry date refers to the last day of that month.</p><p>This medicine does not require any special storage conditions.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p></div>
</text>
</section>
<section>
<title value="6. Contents of the pack and other information"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="6. Contents of the pack and other information"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What LUMYKRAS contains</p><ul><li>The active substance is sotorasib. Each film-coated tablet contains 120 mg of sotorasib.</li><li>The other ingredients are:</li></ul><ul><li>Cellulose, microcrystalline (E460(i))</li><li>Lactose monohydrate</li><li>Croscarmellose sodium (E468)</li><li>Magnesium stearate (E470b)</li></ul><ul><li>The tablets are coated with:</li></ul><ul><li>Polyvinyl alcohol (E1203), titanium dioxide (E171), macrogol 4000 (E1521), talc (E553b), and iron oxide yellow (E172)</li></ul><p>See LUMYKRAS contains lactose and LUMYKRAS contains sodium in section 2. What LUMYKRAS looks like and contents of the pack</p><p>LUMYKRAS is supplied as a yellow, oblong-shaped, film-coated tablet, with AMG on one side and 120 on the other side.</p><ul><li>LUMYKRAS is provided in blisters containing 8 film-coated tablets in packs sizes of 240 film- coated tablets (1 carton with 30 blisters) and multipack with 720 (3 240) film-coated tablets.</li><li>LUMYKRAS is provided in bottles containing 120 film-coated tablets in a pack size of 240 film-coated tablets (1 carton with 2 bottles). Not all pack sizes may be marketed.</li></ul><p>Marketing Authorisation Holder and Manufacturer Amgen Europe B.V., Minervum 7061, 4817 ZK Breda, The Netherlands</p><p>Marketing Authorisation Holder Amgen Europe B.V., Minervum 7061, 4817 ZK Breda, The Netherlands</p><p>Manufacturer Amgen NV, Telecomlaan 5-7, 1831 Diegem, Belgium</p><p>For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:</p><p>Belgi /Belgique/Belgien s.a. Amgen n.v. T l/Tel: +32 (0)2 7752Lietuva Amgen Switzerland AG Vilniaus filialas Tel: +370 5 219 7</p><p>.: +359 (0)2 424 7Luxembourg/Luxemburg s.a. Amgen Belgique/Belgien T l/Tel: +32 (0)2 7752 esk republika Amgen s.r.o. Tel: +420 221 773 Magyarorsz g Amgen Kft. Tel.: +36 1 35 44 Danmark Amgen, filial af Amgen AB, Sverige Tlf: +45 39617Malta Amgen S.r.l. Italy Tel: +39 02 6241Deutschland Amgen GmbH Tel: +49 89 1490Nederland Amgen B.V. Tel: +31 (0)76 5732Eesti Amgen Switzerland AG Vilniaus filialas Tel: +372 586 09Norge Amgen AB Tlf: +47 23308<br/>Amgen . . . : +30 210 3447 sterreich Amgen GmbH Tel: +43 (0)1 50 Espa a Amgen S.A. Tel: +34 93 600 18 Polska Amgen Biotechnologia Sp. z o.o. Tel.: +48 22 581 3France Amgen S.A.S. T l: +33 (0)9 69 363 Portugal Amgen Biofarmac utica, Lda. Tel: +351 21 4220Hrvatska Amgen d.o.o. Tel: +385 (0)1 562 57 Rom nia Amgen Rom nia SRL Tel: +4021 527 3Ireland Amgen Ireland Limited Tel: +353 1 8527Slovenija AMGEN zdravila d.o.o. Tel: +386 (0)1 585 1 sland Vistor hf. S mi: +354 535 7Slovensk republika Amgen Slovakia s.r.o. Tel: +421 2 321 114 Italia Amgen S.r.l. Tel: +39 02 6241Suomi/Finland Amgen AB, sivuliike Suomessa/Amgen AB, filial i Finland Puh/Tel: +358 (0)9 54900K<br/>C.A. Papaellinas Ltd : +357 22741 Sverige Amgen AB Tel: +46 (0)8 6951Latvija Amgen Switzerland AG R gas fili le Tel: +371 257 25United Kingdom (Northern Ireland) Amgen Limited Tel: +44 (0)1223 420This leaflet was last revised in {month YYYY}.</p><p>This medicine has been given conditional approval . This means that there is more evidence to come about this medicine.</p><p>The European Medicines Agency will review new information on this medicine at least every year and this leaflet will be updated as necessary.</p><p>Other sources of information</p><p>Detailed information on this medicine is available on the European Medicines Agency web site:</p></div>
</text>
</section>
</section>
</Composition>
</resource>
</entry>
<entry>
<fullUrl
value="MedicinalProductDefinition/mp167401fb8187f3756835cc75cca90e3c"/>
<resource>
<MedicinalProductDefinition>
<id value="mp167401fb8187f3756835cc75cca90e3c"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"/>
</meta>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><a name="MedicinalProductDefinition_mp167401fb8187f3756835cc75cca90e3c"> </a><p class="res-header-id"><b>Generated Narrative: MedicinalProductDefinition mp167401fb8187f3756835cc75cca90e3c</b></p><a name="mp167401fb8187f3756835cc75cca90e3c"> </a><a name="hcmp167401fb8187f3756835cc75cca90e3c"> </a><a name="mp167401fb8187f3756835cc75cca90e3c-en-US"> </a><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/21/1603/001</p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-type MedicinalProduct}">Medicinal Product</span></p><p><b>domain</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-domain Human}">Human use</span></p><p><b>status</b>: <span title="Codes:{http://hl7.org/fhir/publication-status active}">active</span></p><p><b>legalStatusOfSupply</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi 100000072084}">Medicinal product subject to medical prescription</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: LUMYKRAS 120 mg film-coated tablets</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000001}">Full name</span></p><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000002}">Invented name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000003}">Scientific name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000004}">Strength part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000005}">Pharmaceutical dose form part</span></p></blockquote><h3>Usages</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:ietf:bcp:47 en}">en</span></td></tr></table></blockquote></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/21/1603/001"/>
</identifier>
<type>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-type"/>
<code value="MedicinalProduct"/>
<display value="Medicinal Product"/>
</coding>
</type>
<domain>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-domain"/>
<code value="Human"/>
<display value="Human use"/>
</coding>
</domain>
<status>
<coding>
<system value="http://hl7.org/fhir/publication-status"/>
<code value="active"/>
<display value="active"/>
</coding>
</status>
<legalStatusOfSupply>
<coding>
<system value="https://spor.ema.europa.eu/rmswi"/>
<code value="100000072084"/>
<display
value="Medicinal product subject to medical prescription"/>
</coding>
</legalStatusOfSupply>
<name>
<productName value="LUMYKRAS 120 mg film-coated tablets"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000001"/>
<display value="Full name"/>
</coding>
</type>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000002"/>
<display value="Invented name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000003"/>
<display value="Scientific name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000004"/>
<display value="Strength part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000005"/>
<display value="Pharmaceutical dose form part"/>
</coding>
</type>
</part>
<usage>
<country>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</country>
<jurisdiction>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</jurisdiction>
<language>
<coding>
<system value="urn:ietf:bcp:47"/>
<code value="en"/>
<display value="en"/>
</coding>
</language>
</usage>
</name>
</MedicinalProductDefinition>
</resource>
</entry>
</Bundle>
IG © 2021+ Gravitate Health Project. Package hl7.eu.fhir.ghepi#0.1.0 based on FHIR 5.0.0. Generated 2024-10-14
Links: Table of Contents |
QA Report
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
This joint undertaking receives support from the EU H2020 research and innovation programme and EFPIA.
